

Computers in Critical Care and Pulmonary Medicine

Edited by P. M. Osswald

in Cooperation with

O. Prakash, H.-J. Hartung and H. J. Bender

With 197 Figures and 29 Tables

Springer-Verlag

Berlin Heidelberg New York Tokyo

Table of Contents

Application of Computer Systems in Critical Care K. GEIGER	1
On-line Cardiovascular Applications of Microcomputers in Intensive Care C. PRYS-ROBERTS	8
Organizing and Analyzing Clinical Information Using Table-Based, Graphics-Oriented, Interactive Computer Systems B. J. RANSIL	17
An Attempt to Solve the "Information Explosion" in an Intensive Care Ward D. J. PRICE, J. MASON, and S. SNOWDEN	23
Towards a Coherent Structure of the Anesthetist – Computer Interface S. TRISPEL, H. KLOCKE, G. RAU, and R. SCHLIMGEN	29
Effect of Different Ventilation Patterns on the Intracranial Pressure in Neurologic Patients with Mechanical Ventilation K. M. EINHÄUPL, C. GARNER, G. SCHMIEDER, G. KERSCHER, and R. WIECZOREK	38
Computer Applications in Pulmonary Function Testing M. HEITZ	43
The Assessment of Gas Exchange by Automated Analysis of O ₂ and CO ₂ Alveolar to Arterial Differences: 3 Years Experience in Respiratory Clinical Physiology P. PAOLETTI, E. FORNAI, A. G. NETO, R. PREDILETTO, S. RUSCHI, and C. GIUNTINI	57
Computers in Experimental Pathophysiological Research R. SCHOSSER, H.-P. ENGEL, and K. MESSMER	66
Data Bases in Acute Medicine T. J. STAFFORD, and R. BURNEY	75
Computerized Clinical Records in the Neurosurgical ICU with Self-updating of Some Biological Data R. URCIUOLI, M. KNAFLITZ, G. BALESTRA, M. A. ARBINOLO, M. L. BELLERO, R. BERTINO, C. FRANCO, M. GESSA, and A. GUARNACCIA	78

Organization and Analysis of Data from Patients with Trauma and Hemorrhage W. KELLERMANN, K. PETER, U. JENSEN, Y. SUMMA, and D. NEUMEIER	82
Computer Assisted ICU Monitoring T. OYAMA, H. ISHIHARA, A. MATSUKI, M. YAMASHITA, K. ISOZAKI, and T. SUZUKI	96
Automatic Signal Analysis and Prediction in Intensive Medical Care A. SWOBODA, and E. EPPLE	100
Artifact Processing in a Computerized Intensive Care Unit W. BLEICHER, E. EPPLE, M. KOPP, and H. JUNGER	107
Personal Computers for Gas Exchange Measurements in the ICU G. WIESSPEINER, S. SCHUY, H. METZLER, and W. LIST	116
Integration of a New Computer HP 9816S in the Pulmonary Calculator System HP 47804S. Advantages of Using the Screen for Graphic Presentation of Flow-Volume Curves K. ERDMANN, and J.-P. JANTZEN	123
Measurement of Oxygen Uptake with a New Method H. METZLER, G. WIESSPEINER, and W. F. LIST	130
A Microcomputerassisted System for the Monitoring of Cardiorespiratory Variables in the Critically Ill K. HANKELN, and H. MICHELSEN	134
Selective Lung Ventilation H.-J. HARTUNG, P.-M. OSSWALD, and H. J. BENDER	138
Automated Anesthetic Record Keeping N. TY SMITH	147
Computer Aided Methods to Predict Perioperative Risks U. FELDMANN, P.-M. OSSWALD, H.-J. HARTUNG, and H. LUTZ	162
New Tasks for Medical Informatics? C. O. KÖHLER	184
Artificial Intelligence: the Expert Systems Approach to Medical Consultation E. H. SHORTLIFFE, and L. M. FAGAN	190
Expert Consultation Systems in Medicine P. L. MILLER	198
The Importance of Using a Computer to Provide Pediatric Anesthesia and Emergency Drug Information and Treatment Regimens in the Clinical Setting D. J. ESSIN, D. L. WARNER, M. JAGODOWICZ, and S. N. STEEN	207
Computer Systems in Artificial Ventilations (New Techniques) W. KOLLER, A. ALOY, N. MUTZ, and G. PAUSER	212

Series Dead Space Volume Assessed as the Mean Value of a Distribution Function G. WOLFF, and J. X. BRUNNER	221
Evaluation of Indices for Respiratory Mechanics from an Automated System B. FRIBERG, M. FORSSBLAD, S. BAEHRENDTZ, J. HULTING, K. EKENBÄCK, M. JOHANSSON, and G. MATELL	228
Mathematical Modelling for Prediction of Optimal Ventilator Settings R. RUDOWSKI, G. MATELL, K. EKENBÄCK, C. SPANNE, and B. OSSMER	235
Indications for the Application of Closed Loop Systems in Perioperative Medicine R. D. WESTENSKOW	247
Glucose-Insulin-Potassium Therapy Guided by a Glucose-Controlled Insulin Infusion System in Acute Myocardial Infarction G. MÜLLER-ESCH, P. BALL, U. BEKEMEYER, H. DJONLAGIC, A. HAUPTMANN, K. HEIDBÜCHEL, A. PETERS, R. TYBUSSEK, W. G. WOOD, and P. C. SCRIBA	252
Changes in Monitoring Methods Caused by the Use of Intelligent Bedside Equipment E. EPPLE, W. BLEICHER, M. KOPP, and H. JUNGER	259
Automated Arrhythmia Detection in Intensive Care C. ZEELLENBERG, S. H. MEIJ, M. R. HOARE, and P. G. HUGENHOLTZ	265
Monitoring Intracranial Pressure – Nuisance to, or Advantages for, Ward Personnel K. WIEDEMANN, G. SCHMIDT, and M. MÜLLER	280
Computerized Neuromonitoring M. R. GAAB	290
Computer-Assisted Monitoring of Intracranial Pressure in Stroke A. HAASS, T. MADLER, and K. SCHIMRIGK	307
Microprocessor-Controlled Registration and Evaluation of Respiratory Pressure-Volume Diagrams in ICUs W. KELLERMANN, Y. SUMMA, and K. PETER	311
NAPROS – A semiautomatic and easy to use anaesthetic record system D. WINTER, and P.-M. OSSWALD	319
A Real Time Pattern Recognition Program for Continuous Processing of Cardiovascular Biosignals M. MAIWALD	329
Microcomputer-Assisted ICP Monitoring in Neurological Patients G. SCHMIEDER, C. GARNER, K. M. EINHÄUPL, K. SIEGL, and G. KUFNER	334

Glucose-Insulin-Potassium Therapy Guided by a Glucose-Controlled Insulin Infusion System in Acute Myocardial Infarction

G. MÜLLER-ESCH, P. BALL, U. BEKEMEYER, H. DJONLAGIC, A. HAUPTMANN, K. HEIDBÜCHEL, A. PETERS, R. TYBUSSEK, W. G. WOOD, and P. C. SCRIBA

A number of hormonal and metabolic alterations have been observed during acute myocardial infarction (AMI): There is a rapid increase of catecholamine and cortisol secretion; free fatty acid (FFA) serum levels are markedly elevated (Gupta et al. 1969; Januszewicz et al. 1971; Vetter et al. 1974); and insulin secretion may be inappropriately low. These alterations result in a disturbance of glucose utilization, so-called stress hyperglycemia. Moreover, under these conditions and due to the accumulation of free fatty acids in the ischemic myocardium, severe ventricular arrhythmias as well as a progression of myocardial cell damage are likely to occur (Kurien and Oliver 1970; Kurien et al. 1971; Oliver et al. 1968).

Glucose-insulin-potassium infusions (GIK) in AMI have been used in a number of clinical trials in order to overcome these deleterious effects (Mantle et al. 1981; Rogers et al. 1976, 1979; Sodi-Palleres et al. (1962)). Some of the postulated benefits of GIK treatment in AMI are: a decrease of FFA, a reduction of potassium efflux, a repletion of intracellular potassium stores, an enhancement of myocardial glucose utilization, a reduction of myocardial oxygen consumption, and an improvement in coronary perfusion. These changes should reduce severe life-threatening arrhythmias, limit infarct size, improve left ventricular function, and reduce hospital mortality (von Arnim and Bolte 1980; Brachfeld 1973; Kurien et al. 1971; Manke et al. 1981; Oliver 1973). With an "open loop" fixed GIK regime as in the studies mentioned above, severe hyperglycemia as well as hypoglycemia were not infrequently seen, because the degree of impairment of the insulin sensitivity could not be predicted. We therefore decided to use a glucose – controlled insulin infusion system (GCIIS); this involves applying "closed-loop" control during treatment with GIK according to the individual insulin sensitivity and thereby studying hormonal and metabolic patterns in AMI.

Methods

Nine patients (eight male, one female; age 61.8 ± 8.8 years) with AMI admitted to our intensive care unit within 12 h after onset of chest pain received GIK for 24 h. The solution contained 430 g glucose, 166 U porcine regular insulin, and 133 mEq KCl per liter. The infusion rate was 0.9 ml/kg/h. Additional feedback – controlled insulin and/or glucose was given by the GCIIS (Biostator-Controller). The following constants were chosen: Mode 3:1, Var 100, BI 80, BD 60, and FI 500–1000. Insulin concentra-




Fig. 1. Schematic diagram of device used for processing of GCIS data

tion of the GIK solution was increased when blood glucose could not be kept below 250 mg/dl. Insulin, C-peptide, cortisol, GH, prolactin, and lactate were determined at 6-h intervals. FFAs were measured by gas-liquid chromatography (Tserng et al. 1981). Figure 1 shows a schematic diagram of the technical equipment. The patient is connected to the GCIS. By means of an interface all data for blood glucose (BG), insulin infusion rate (IR), and dextrose infusion rate (DR) are transferred directly from the Biostator to a microcomputer for further processing (Muller-Esch et al. 1984). The microcomputer fulfils several functions:

1. *Monitoring:* BG, IR, and DR are plotted continuously
2. *Manual input:* comments concerning, for example, the actual therapy can be entered via the keyboard
3. *Calculations:* a BASIC computer program has been developed for the calculation of the glycemic indices mean blood glucose (MBG), M-value, and MAGE (Muller-Esch et al. 1984)
4. *Printer and floppy disks:* all values for BG, IR, and DR, as well as comments which appear in their time-related positions, and calculated parameters are plotted and documented on 5-in. floppy disks.

Results

The insulin sensitivity – as measured by blood glucose concentrations and total insulin requirements during GIK – varied markedly. Figure 2a is an example from a patient with high insulin requirements. Initial BG is about 110 mg/dl, rising to more than 250 mg/dl after starting GIK infusion. Despite submaximal additional feedback-controlled insulin by the GCIIS, BG did not fall below 200 mg/dl. In contrast, in the patient shown in Fig. 2b, euglycemia during GIK could be obtained with only minor additional feedback-controlled insulin administration. And in another patient, additional feedback-controlled dextrose had to be given to prevent hypoglycemia during GIK, MBG being in the range of about 80 mg/dl (Fig. 2c).

According to these data we can divide our patients into two groups: in five patients (group A), a total of 309 ± 52 U insulin/24 h was sufficient to maintain fair glycemic control (Table 1, top). In four patients, however (group B), insulin concentration of GIK had to be partially multiplied because of marked hyperglycemia: insulin requirements were 1193 ± 258 U/24 h; despite this, we did not achieve nearly normal BG values or nearly normal glycemic indices (Table 1, bottom).

When compared to the “low insulin” group, the “high insulin” group presented with higher serum insulin levels *before* GIK treatment. *During* therapy, this group had higher values for C-peptide, cortisol, prolactin, and lactate. GH and glucagon did not differ significantly (Table 1).

Table 1. Insulin, C-peptide, glucagon, cortisol, GH, prolactin, and lactate serum levels during GCIIS-guided GIK therapy in patients with low insulin requirements (group A) and high insulin requirements (group B). The glycemic indices MBG, MAGE, and M-value are also shown. ($P < 0.05$ vs. group A)

<i>Group A (309 ± 52 U insulin/24 h, n = 5)</i>					
	0 h	6 h	12 h	18 h	24 h
Insulin (mU/l)	11.3 ± 7.5	191 ± 48	227 ± 181	289 ± 198	316 ± 219
C-peptide (µg/l)	2.6 ± 1.8	1.0 ± 0.7	0.6 ± 0.5	2.5 ± 4.1	2.1 ± 2.5
Glucagon (ng/l)	140 ± 25	158 ± 53	160 ± 84	176 ± 82	164 ± 74
Cortisol (ng/ml)	233 ± 131	172 ± 98	196 ± 95	212 ± 112	188 ± 92
GH (ng/ml)	2.1 ± 1.5	4.4 ± 2.9	4.2 ± 2.0	3.5 ± 2.5	2.1 ± 1.6
Prolactin (µU/ml)	398 ± 131	258 ± 64	242 ± 72	225 ± 79	248 ± 51
Lactate (mmol/l)	1.4 ± 0.5	2.0 ± 1.0	1.6 ± 0.8	1.3 ± 0.6	1.1 ± 0.3
MBG: 94 ± 28	MAGE: 51 ± 8			M-value: 17 ± 7	
<i>Group B (1193 ± 258 U insulin/24 h, n = 4)</i>					
	0 h	6 h	12 h	18 h	24 h
Insulin (mU/l)	● 43 ± 22	● > 500	● > 500	● > 500	● > 500
C-peptide (µg/l)	8.0 ± 7.5	● 13.4 ± 12.9	● 15.0 ± 14.3	21.6 ± 22.9	12.3 ± 15.6
Glucagon (ng/l)	152 ± 77	87 ± 62	90 ± 73	124 ± 140	15.1 ± 169
Cortisol (ng/ml)	301 ± 224	● 418 ± 135	● 418 ± 174	● 412 ± 203	● 418 ± 186
GH (ng/ml)	3.1 ± 2.4	6.1 ± 2.4	3.0 ± 1.8	1.7 ± 1.4	1.5 ± 1.2
Prolactin (µU/ml)	590 ± 281	● 549 ± 182	● 489 ± 150	● 532 ± 135	● 681 ± 191
Lactate (mmol/l)	● 2.7 ± 1.3	● 3.5 ± 0.8	2.7 ± 0.9	● 2.7 ± 1.2	● 3.5 ± 1.4
● MBG: 234 ± 42	● MAGE: 159 ± 57			● M-value: 46 ± 15	




Fig. 2a




Fig. 2b

Fig. 2a-c. Blood glucose (BG), insulin infusion rate (IR), and dextrose infusion rate (DR) during GCIIS-guided GIK therapy in three patients with AMI




Fig. 2c

Table 2. Insulin, C-peptide, glucagon, cortisol, GH, prolactin, lactate, and blood glucose (BG) levels in seven conventionally treated patients with AMI as compared to four patients under GCIIS-guided GIK therapy (group B). ● P < 0.05 vs. controls

Controls (n = 7)

	0 h	6 h	12 h	18 h	24 h
Insulin (mU/l)	35 ± 17	18 ± 11	26 ± 24	26 ± 24	39 ± 34
C-peptide (µg/l)	5.4 ± 2.9	4.9 ± 3.3	4.7 ± 3.2	6.4 ± 3.3	8.6 ± 6.2
Glucagon (ng/l)	323 ± 446	373 ± 537	348 ± 412	431 ± 497	443 ± 407
Cortisol (ng/ml)	239 ± 145	266 ± 192	218 ± 108	247 ± 171	229 ± 163
GH (ng/ml)	2.1 ± 3.1	2.9 ± 3.8	2.4 ± 2.7	3.3 ± 6.5	2.6 ± 2.6
Prolactin (µU/ml)	834 ± 895	445 ± 256	273 ± 106	228 ± 50	306 ± 74
Lactate (mmol/l)	2.1 ± 2.1	2.1 ± 1.8	1.7 ± 1.1	1.4 ± 0.5	1.4 ± 0.4
BG (mg/dl)	147 ± 38	157 ± 49	122 ± 23	144 ± 48	162 ± 72

Group B (1193 ± 258 U insulin/24 h, n = 4)

	0 h	6 h	12 h	18 h	24 h
Insulin (mU/l)	43 ± 22	> 500	> 500	> 500	> 500
C-peptide (µg/l)	8.0 ± 7.5	13.4 ± 12.9	● 15.0 ± 14.3	21.6 ± 22.9	12.3 ± 15.6
Glucagon (ng/l)	152 ± 77	87 ± 62	90 ± 73	124 ± 140	151 ± 169
Cortisol (ng/ml)	301 ± 224	418 ± 135	● 418 ± 174	412 ± 203	418 ± 186
GH (ng/ml)	3.1 ± 2.4	6.1 ± 2.4	3.0 ± 1.8	1.7 ± 1.4	1.5 ± 1.2
Prolactin (µU/ml)	590 ± 281	549 ± 182	● 489 ± 150	● 532 ± 135	● 681 ± 191
Lactate (mmol/l)	2.7 ± 1.3	3.5 ± 0.8	2.7 ± 0.9	● 2.7 ± 1.2	● 3.5 ± 1.4

MBG: 234 ± 42

MAGE: 159 ± 57

M-value: 46 ± 15




Fig. 3. Free fatty acids (FFA) during GCIIS-guided GIK therapy in two patients with AMI

Seven conventionally treated patients with AMI served as controls (Table 2). In comparison with these patients without GIK, group B had higher serum levels for C-peptide, cortisol, prolactin, and lactate.

Serial FFA measurements in two patients show a decrease of FFA under GIK below the arrhythmia threshold (Oliver et al. 1968) of 1200 $\mu\text{mol/l}$ (Fig. 3).

Discussion

Because of the small number of patients we are not yet able to decide whether the observed hormonal-metabolic differences between the groups are directly correlated to the infarct size or whether they reflect different systemic reactions, different hormonal-metabolic patterns, during AMI.

In conclusion, these preliminary data indicate that the impairment of insulin sensitivity and glucose utilization during AMI varies markedly. FFA can be reduced below the arrhythmia threshold. Further studies should compare metabolic, hemodynamic, and antiarrhythmogenic effects of GCIIS-guided GIK support in patients with AMI.

References

- Von Arnim T, Bolte HD (1980) Therapie mit Glukose-Insulin beim kardiogenen Schocksyndrom. In: Brückner JB (ed) *Kreislaufschock*. Springer, Berlin Heidelberg New York, pp 500–505
- Brachfeld N (1973) The glucose-insulin-potassium (GIK) regimen in the treatment of myocardial ischemia. *Circulation* 47: 459–462
- Gupta DK, Jewitt DE, Young R, Hartog M, Opie LM (1969) Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction. *Lancet* 2: 1209–1213
- Januszewicz W, Sznajdermann M, Ciświcka-Sznajdermann M, Wocial B, Rymaszewski Z (1971) Plasma free fatty acid and catecholamine levels in patients with acute myocardial infarction. *Br Heart J* 33: 716–718
- Kurien VA, Oliver MF (1970) A metabolic cause for arrhythmias during acute myocardial hypoxia. *Lancet* 1: 813–815
- Kurien VA, Yates PA, Oliver MF (1971) The role of free fatty acids in the production of ventricular arrhythmias after acute coronary artery occlusion. *Eur J Clin Invest* 1: 225–241

- Mantle JA, Rogers WJ, Smith LR, McDaniel HG, Papapietro JE, Russell RO, Rackley CH (1981) Clinical effects of glucose-insulin-potassium on left ventricular function in acute myocardial infarction: results from a randomized clinical trial. *Am Heart J* 102: 313–324
- Müller-Esch G, Peters A, Göhl M, Heidebüchel K, Scriba PC (1984) Simplified evaluation and documentation of data from glucose controlled insulin infusion systems (GCIIS). *Biomed Technik* 29: 62–66
- Oliver MF (1973) Glucose, insulin, potassium in acute myocardial infarction. *Acta Cardiol [Suppl]* 17: 257–262
- Oliver MF, Kurien VA, Greenwood TW (1968) Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. *Lancet* 1: 710–715
- Rogers WJ, Stanley AW, Breinig JB, Prather JW, McDaniel MG, Moraski RE, Mantle JA, Russell RO Jr, Rackley CE (1976) Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. *Am Heart J* 92: 441–454
- Rogers WJ, Segall PH, McDaniel HG, Mantle JA, Russell RO Jr, Rackley CE (1979) Prospective randomized trial of glucose-insulin-potassium in acute myocardial infarction. Effects on myocardial hemodynamics, substrates and rhythm. *Am J Cardiol* 43: 801–809
- Sodi-Pallares D, Testelli MK, Fishleder BL, Bisteni A, Medrano GA, Friedland C, DeMicheli A (1962) Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. *Am J Cardiol* 9: 166–181
- Tserng KY, Kliegmann RM, Miettinen EL, Kalhan SC (1981) A rapid, simple, and sensitive procedure for the determination of free fatty acids in plasma using glass capillary column gas-liquid chromatography. *J Lipid Res* 22: 852–858
- Vetter NJ, Strange RC, Adams W, Oliver NF (1974) Initial metabolic and hormonal response to acute myocardial infarction. *Lancet* 1: 284–289